Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 11:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 392 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertension, Glaucoma, Open-Angle Clear all
Completed Phase 3 Interventional

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70

NCT00047541
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Alcon Investigational Agent
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 14, 2026, 11:16 AM EDT
Recruiting Phase 3 Interventional

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07495852
View directory record Official record
Conditions
Glaucoma
Interventions
Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops
Drug · Procedure · Other
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dothan, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 14, 2026, 11:16 AM EDT
Withdrawn No phase listed Observational

Prevalence of Dyschromatopsia in Glaucoma Patients

NCT01994564
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 14, 2026, 11:16 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

NCT02207621
View directory record Official record
Conditions
Ocular Hypertension, Open-angle Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo, AR-13324 Ophthalmic Solution 0.02% BID
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
Up to 99 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 14, 2026, 11:16 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00651859
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Bimatoprost 0.01% Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution, Bimatoprost Vehicle Ophthalmic Solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
20 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 14, 2026, 11:16 AM EDT
Active, not recruiting No phase listed Observational

Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes

NCT05506423
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
CycloPen Cyclodialysis System
Device
Lead sponsor
Iantrek, Inc.
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Newport Beach, California • Cape Coral, Florida • DeLand, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 14, 2026, 11:16 AM EDT
Completed No phase listed Observational

Comparison of Gonioscopy With Cirrus and Visante

NCT01895686
View directory record Official record
Conditions
Open Angle Glaucoma, Narrow Angles, Angle Closure Glaucoma
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 14, 2026, 11:16 AM EDT
Completed Phase 3 Interventional Results available

A Long-term Safety Study of Once-daily Travatan

NCT00051168
View directory record Official record
Conditions
Glaucoma, Open-angle, Ocular Hypertension
Interventions
Travatan
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 14, 2026, 11:16 AM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

NCT02558374
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 14, 2026, 11:16 AM EDT
Completed No phase listed Observational Results available

A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs

NCT00823043
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
timolol hemihydrate, timolol maleate
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 14, 2026, 11:16 AM EDT
Not listed Phase 1 Interventional

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

NCT06267274
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Bakersfield, California • Newport Beach, California • Morrow, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 14, 2026, 11:16 AM EDT
Completed No phase listed Observational Results available

A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System

NCT05044793
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
OMNI® Surgical System
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Wichita, Kansas • Oklahoma City, Oklahoma • Jenkintown, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 14, 2026, 11:16 AM EDT
Terminated Not applicable Interventional

Glaucoma Eye Drop Instillation: Impact of Education

NCT01416415
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Video education on proper eye drop instillation technique, Placebo video education on healthy eating tips
Other
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 85 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 14, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension

NCT01223378
View directory record Official record
Conditions
Intraocular Pressure
Interventions
BOL-303259-X, Latanoprost
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 14, 2026, 11:16 AM EDT
Completed Not applicable Interventional

A Comparison of Two Ab Interno Procedures in the Treatment of Glaucoma in Patients Undergoing Cataract Extraction

NCT02784249
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Goniotomy, Trabecular Micro-Bypass Stent, Cataract Extraction
Procedure · Device
Lead sponsor
New World Medical, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 14, 2026, 11:16 AM EDT
Recruiting No phase listed Observational

DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma

NCT06933836
View directory record Official record
Conditions
Open Angle Glaucoma (OAG)
Interventions
DSLT enables newly diagnosed patients to remain well controlled and off medications
Device
Lead sponsor
Barnet Dulaney Perkins Eye Centers
Network
Eligibility
30 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 14, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

NCT02143843
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost
Drug
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Artesia, California • La Jolla, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 14, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT05913232
View directory record Official record
Conditions
Glaucoma Open-Angle Primary, Ocular Hypertension
Interventions
H-1337 0.6%, H-1337 1.0%, H-1337 Placebo, Timolol 0.5%
Drug
Lead sponsor
D. Western Therapeutics Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Glendale, California • Colorado Springs, Colorado • Lakeland, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 14, 2026, 11:16 AM EDT
Completed Phase 2 Interventional

Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

NCT04830397
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
QLS-101, Timolol Maleate
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Albany, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 14, 2026, 11:16 AM EDT
Active, not recruiting Not applicable Interventional

Electrical Stimulation for the Treatment of Glaucoma

NCT05626491
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open-Angle
Interventions
Repetitive, Transorbital Alternating Current Stimulation (rtACS), Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Palo Alto, California • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 11:16 AM EDT
Completed Phase 4 Interventional Results available

Circadian Ocular Perfusion Pressure and Ocular Blood Flow

NCT00800540
View directory record Official record
Conditions
Glaucoma
Interventions
Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension, Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 14, 2026, 11:16 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma

NCT00451152
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Oct 14, 2026, 11:16 AM EDT
Completed Phase 1 Interventional

Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension

NCT00515424
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
RKI983
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Timeline
Started 2007
U.S. locations
5
States / cities
Artesia, California • Rochester, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 14, 2026, 11:16 AM EDT
Completed Phase 2Phase 3 Interventional

Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00691717
View directory record Official record
Conditions
Open-angle Glaucoma, Oular Hypertension
Interventions
Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Sterile Suspension, 75 mg/mL, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Oct 14, 2026, 11:16 AM EDT